Skip to main content
. Author manuscript; available in PMC: 2018 Jan 5.
Published in final edited form as: Mol Cell Endocrinol. 2016 Oct 6;439:1–9. doi: 10.1016/j.mce.2016.10.006

Figure 8. Model of MAGE-A11 interactions with Skp2, cyclin A and E2F1.

Figure 8

Skp2-mediated protein degradation involves a cyclin A-cdk2-p27Kip1 complex that is regulated by MAGE-A11 interaction with Skp2, cyclin A and E2F1. MAGE-A11 contains a cyclin A peptide binding motif homologous to the cyclin A binding site in Skp2. MAGE-A11 interaction with cyclin A stabilizes cyclin A at low Skp2 levels, and promotes cyclin A degradation at higher levels of Skp2. MAGE-A11 interaction with cyclin A is not inhibited by the p27Kip1 cyclin-dependent kinase inhibitor that inhibits Skp2 interaction with cyclin A. However, MAGE-A11 interaction with cyclin A is inhibited by Skp2. MAGE-A11 mediates a stable complex between Skp2 and E2F1 that sequesters Skp2 and blocks Skp2-mediated down-regulation of E2F1.